Teijin (3401) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 Oct, 2026Executive summary
Q1 FY2025 revenue was ¥243,117 million, down 4.8% YoY; adjusted operating income fell 24.5% to ¥7,847 million, mainly due to Materials maintenance and aramid restructuring costs.
Net loss attributable to owners was ¥740 million, versus prior-year profit of ¥4,451 million.
Financial highlights
EBITDA was ¥23.2 billion, down ¥6.2 billion YoY; adjusted operating income margin declined to 3.2%.
Operating income fell to ¥2,295 million from ¥8,041 million, while profit before tax was ¥62 million versus ¥8,389 million.
Financial income and costs worsened ¥1.9 billion YoY, mainly from foreign-exchange losses as the prior-year benefit from yen depreciation faded.
Structural reform costs totaled ¥4.1 billion, including aramid measures, closure of the Arnhem specialty pulp mill and welfare-facility impairments.
Operating cash flow increased to ¥16,622 million from ¥8,631 million; free cash flow improved to -¥1.9 billion from -¥8.4 billion.
Outlook and guidance
FY2025 revenue forecast is ¥860 billion, down ¥145.5 billion YoY, largely due to the North American Composites exit; adjusted operating income guidance remains ¥35 billion, up ¥7.4 billion YoY.
Profit attributable to owners is forecast at ¥12 billion, down ¥16.3 billion YoY; annual dividend guidance remains ¥50 per share.
Materials outlook: revenue ¥330 billion and adjusted operating income ¥8 billion; cost reforms and transfers are expected to recover ¥9 billion against a ¥7 billion negative spread impact.
Fibers and Products Converting outlook: revenue ¥350 billion and adjusted operating income ¥18 billion, broadly flat YoY; Industrial Materials is expected to remain strong.
Health Care outlook: revenue ¥135 billion and adjusted operating income ¥12.5 billion; Other businesses forecast revenue of ¥45 billion and adjusted operating income of ¥4.5 billion.
Latest events from Teijin
- Profit and AOI surged on asset sales, with higher outlook and ongoing segment reorganization.3401
Q1 2027 - Aiming for customer-driven growth, profitability, and strong ESG performance by FY2028.3401
Investor presentation - FY2026 targets profit recovery and growth amid restructuring and stable dividends.3401
Q4 2026 - Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 2026 - Protect PC earnings while scaling non-PC growth, high-value products and circular materials.3401
Investor Day 2025 - Focus on home healthcare, rare diseases, and innovation drives long-term growth.3401
Investor Update - Q1 earnings rebounded, FY2024 guidance rose and the planned Infocom sale advanced.3401
Q1 2025 - A composites impairment drove a first-half loss as FY2024 guidance and dividends rose.3401
Q2 2025